Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 5/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5402531 | 0.93 | LTA4H (0.45) | LTA4HPTGS1PTGS2ACHE | |
| SCHEMBL5418655 | 0.93 | PTGS1 (0.51) | LTA4HKMT2APTGS1PTGS2ALDH1A1 | |
| SCHEMBL5406376 | 0.91 | MAPT (0.43) | LTA4HPTGS1PTGS2ACHE | |
| SCHEMBL5402972 | 0.91 | ACHE (0.43) | LTA4HPOLBKMT2APTGS1PTGS2 | |
| SCHEMBL5408881 | 0.90 | PTGS1 (0.39) | LTA4HPTGS1PTGS2ACHECACNA1B | |
| SCHEMBL5407260 | 0.89 | CACNA1B (0.49) | LTA4HPTGS1PTGS2ACHECACNA1B | |
| SCHEMBL5392936 | 0.89 | KMT2A (0.41) | LTA4HPOLBKMT2ACACNA1BALDH1A1 | |
| SCHEMBL5397997 | 0.88 | MAPT (0.43) | POLBKMT2APTGS1PTGS2ACHE | |
| SCHEMBL5417237 | 0.88 | KMT2A (0.44) | POLBKMT2APTGS1PTGS2ALDH1A1 | |
| SCHEMBL5392580 | 0.86 | CACNA1B (0.50) | LTA4HPTGS1PTGS2ACHECACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169782-B2 | Aryl substituted thiazolidinones and the use thereof | EURO-CELTIQUE S.A. (LU) | 2007-01-30 | — | — | US | claimed |
| US-20040176364-A1 | Aryl substituted thiazinidinones and the use thereof | EURO-CELTIQUE S.A. (LU) | 2004-09-09 | — | — | US | claimed |
| EP-1417187-A1 | ARYL SUBSTITUTED THIAZOLIDINONES AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2004-05-12 | — | — | EP | claimed |
| US-20030109521-A1 | Aryl substituted thiazolidinones and the use thereof | EURO-CELTIQUE, S.A. | 2003-06-12 | — | — | US | claimed |
| WO-2003008398-A1 | ARYL SUBSTITUTED THIAZOLIDINONES AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2003-01-30 | — | — | WO | claimed |
| US-7169782-B2 | Aryl substituted thiazolidinones and the use thereof | EURO-CELTIQUE S.A. (LU) | 2007-01-30 | — | — | US | disclosed |
| US-20040176364-A1 | Aryl substituted thiazinidinones and the use thereof | EURO-CELTIQUE S.A. (LU) | 2004-09-09 | — | — | US | disclosed |
| EP-1417187-A1 | ARYL SUBSTITUTED THIAZOLIDINONES AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2004-05-12 | — | — | EP | disclosed |
| US-20030109521-A1 | Aryl substituted thiazolidinones and the use thereof | EURO-CELTIQUE, S.A. | 2003-06-12 | — | — | US | disclosed |
| WO-2003008398-A1 | ARYL SUBSTITUTED THIAZOLIDINONES AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109521-A1 | Aryl substituted thiazolidinones and the use thereof | CACNA1S, CACNA1I, CACNA1C | LTA4H 472/4885POLB 2768/4885KMT2A 3010/4885 |
| US-20040176364-A1 | Aryl substituted thiazinidinones and the use thereof | CACNA1S, CACNA1I, NLN | LTA4H 582/4885POLB 2449/4885KMT2A 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.